Luye Pharma Group: Luye Pharma Grants Exeltis Exclusive Commercialization Rights to Its Innovative Alzheimer's Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Mexico and Poland

BASEL, Switzerland, March 31, 2022 /PRNewswire/ -- Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into agreements with Exeltis Pharma

Related Keywords

China ,Mexico ,Japan ,Poland ,Switzerland ,Spain ,Japanese ,Luye Pharma ,Exeltis Pharma ,Insud Pharma ,Bruno Delie ,Exeltis Pharmaceuticals Holding ,Luye Pharma Group ,Prnewswire Luye Pharma Group ,Women Health ,Alzheimer Disease International ,Alzheimer Association ,Insud Pharma Group ,Pharma Group ,Luye Pharma Switzerland ,Rivastigmine Multi Day Transdermal Patch ,General Manager ,Central Nervous System ,Disease Facts ,Alzheimer Report ,Luye ,Dharma ,Group ,Migrants ,Exeltis ,Exclusive ,Ommercialization ,Tights ,Nnovative ,Lzheimer ,Disease ,Treatment ,Ivastigmine ,Ulti ,Transdermal ,Watch ,